+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases



Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases



Clinical Chemistry 45(8 Pt 1): 1240-1247



Background: The alteration of the bone microenvironment as a consequence of skeletal metastases is poorly understood. The aim of this study was to search for patterns of bone markers in relation to primary tumor type, bone pain, and number of sites involved in patients with bone metastases. Methods: We studied 323 patients with bone metastases from various primary malignancies. We sequentially measured the serum concentrations of bone alkaline phosphatase (by an electrophoretic technique (BALP)), carboxy-terminal telopeptide of type I collagen (ICTP), calcium (CaS), intact parathyroid hormone (PTH), and the fasting urinary excretion of calcium (Ca:Cr). Immunoradiometric serum bone alkaline phosphatase (I-BALP) and urinary excretion of deoxypyridinoline (DPYD) were also assessed in the 175 cases. Data were analyzed as a function of bone pain (assessed by a validated pain questionnaire), the number of radiographically confirmed sites of bone involvement, and the most frequent primarytumor types: breast cancer (BC; 124 patients), prostate cancer (PC; 90 patients), and non-small cell lung cancer (LC; 49 patients). Results: Serum BALP and I-BALP correlated with the number of radiologically identified blastic bone lesions. BALP and I-BALP were more frequently increased in PC (72% for both measurements) than in BC (50% and 60%, respectively) or LC (3% and 5%, respectively; P <0.001 for BALP and P = 0.001 for I-BALP). ICTP and DPYD values did not differ among PC, BC, and LC, but they did show a direct relationship with the disease extent in bone (P <0.001). CaS and Ca:Cr did not vary significantly according to the bone tumor burden. Bone pain directly correlated with ICTP (P <0.001), DPYD (P = 0.002), CaS (P <0.002), and Ca:Cr (P = 0.001), whereas the relationship was inverse for serum PTH (P = 0.002). When patients were stratified according to the primary tumor, ICTP correlated with the bone pain in all subsets (P <0.005, <0.005, and <0.001 for BC, PC, and LC, respectively), as did CaS and Ca:Cr in LC patients (P = 0.01 and 0.02, respectively) but not in PC and BC patients. Conclusions: The patterns of bone turnover markers differ among the primary tumor types. Both resorption and formation markers reflect the number of radiographically identified sites of bone metastases, whereas resorption markers and serum calcium but not formation markers correlate with bone pain.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 010468456

Download citation: RISBibTeXText

PMID: 10430790


Related references

Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases. Breast Cancer 24(2): 245-253, 2017

Bone Pain And Bone Targeting Agent (Bta) Treatment Patterns In Patients With Bone Metastases (Bms) From Breast Cancer (Bc) In Real World Setting In Europe. Value in Health 18(7): A493, 2015

The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone disease. 3. PTH and osteoblasts, the relationship between bone turnover and bone loss, and the state of the bones in primary hyperparathyroidism. Metabolism 25(9): 1033-1069, 1976

The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone disease. Part III of IV parts; PTH and osteoblasts, the relationship between bone turnover and bone loss, and the state of the bones in primary hyperparathyroidism. Metabolism: Clinical and Experimental 25(9): 1033-1069, 1976

Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid TUGAMO study. British Journal of Cancer 108(12): 2565-2572, 2013

The actions of parathyroid hormone on bone relation to bone remodeling and turnover calcium homeostasis and metabolic bone disease part 4 mechanisms of calcium transfer between blood and bone and their cellular basis morphological and kinetic approaches o bone turnover. Metabolism Clinical and Experimental 25(7): 809-844, 1976

The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone disease. Part I of IV parts: mechanisms of calcium transfer between blood and bone and their cellular basis: morphological and kinetic approaches to bone turnover. Metabolism: Clinical and Experimental 25(7): 809-844, 1976

Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents. Clinical Cancer Research 22(23): 5713-5721, 2016

Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases. Journal of Bone and Mineral Research 20(9): 1543-1547, 2005

Biochemical evaluation of bone turnover in cancer patients with bone metastases: Relationship with radiograph appearances and disease extension. British Journal of Cancer 73(12): 1581-1587, 1996

Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension. British Journal of Cancer 73(12): 1581-1587, 1996

Inability of bone turnover marker as a strong prognostic indicator in prostate cancer patients with bone metastasis: Comparison with the extent of disease (EOD) grade. Prostate 38(1): 28-34, 1999

Bone pain palliation with strontium-89 in breast cancer patients with bone metastases and refractory bone pain. European Journal of Nuclear Medicine 22(10): 1101-1104, 1995

The actions of parathyroid hormone on bone relation to bone remodeling and turnover calcium homeostasis and metabolic bone disease part 3 parathyroid hormone and osteo blasts the relationship between bone turnover and bone loss and the state of the bonesin primary hyper parathyroidism. Metabolism Clinical and Experimental 25(9): 1033-1069, 1976

Prospective study of signalling pathways in myeloma bone disease with regard to activity of the disease, extent of skeletal involvement and correlation to bone turnover markers. European Journal of Haematology 97(2): 201-207, 2016